A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis
Phase of Trial: Phase I/II
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Pomalidomide (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms POMINC
- 25 Jun 2017 Results (n=38) from cohort 1 of the study, presented at the 22nd Congress of the European Haematology Association.
- 06 Dec 2016 Updated results (n=37) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 03 Nov 2016 According to Incyte Corporation media release, data will be presented at 58th Annual American Society of Hematology (ASH) meeting 2016.